Drug Trial Radar · NCT07801222
A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jan 19, 2029
Study completion May 21, 2030
Sponsor
- Lead sponsor
- SOTIO Biotech a.s.Industry
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT106, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.
Conditions
- Osteosarcoma Metastatic
- Soft Tissue Sarcoma (STS)
- Osteosarcoma, Advanced
Interventions
SOT106Biological
SOT106 is a LRRC15-directed monoclonal antibody conjugated to a linker-payload, Monomethyl auristatin E
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT106Time frame: At the end of Cycle 1 (one cycle is 21 days)
- Part B: Optimal dose of SOT106 for subsequent clinical trialsTime frame: Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)
- Part B: Objective Response Rate (ORR) of SOT106Time frame: From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 10 months
- Part B: Duration of Response (DoR) of SOT106Time frame: From the date of first documented objective response until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, assessed up to approximately 10 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arensia Exploratory Medicine Research Unit, Institute of Oncology
Chisinau, Moldova
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.